Sangamo Therapeutics
SGMO
SGMO
112 hedge funds and large institutions have $27.7M invested in Sangamo Therapeutics in 2025 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 30 increasing their positions, 32 reducing their positions, and 24 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
less repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
less ownership
Funds ownership: →
less funds holding
Funds holding: →
20% less capital invested
Capital invested by funds: $34.5M → $27.7M (-$6.75M)
33% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 24
Holders
112
Holding in Top 10
–
Calls
$756K
Puts
$727K
Top Buyers
| 1 | +$1.99M | |
| 2 | +$692K | |
| 3 | +$658K | |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$345K |
| 5 |
Squarepoint
New York
|
+$332K |
Top Sellers
| 1 | -$1.31M | |
| 2 | -$692K | |
| 3 | -$561K | |
| 4 |
Millennium Management
New York
|
-$437K |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$430K |
